Clinical Trials Logo

Clinical Trial Summary

The study is a randomised, double-blinded, placebo-controlled, crossover study enrolling 10 healthy male participants. Each participant will undergo four separate study days in randomised order. Each study day encompasses a continous 90-minute i.v. infusion with either placebo, glucose-dependent insulinotropic polypeptide (GIP), alanine or GIP + alanine. The primary objective of the study is to find out whether intravenous administration of the naturally occuring gut hormone GIP and the amino acid alanine, separately and combined, results in additive or synergistic glucagonotropic effects during euglycaemic conditions in healthy participants. Secondary objectives are to disclose the effect of the abovementioned interventions on insulin secretion and circulating levels of total and individual amino acids.


Clinical Trial Description

n/a


Study Design


NCT number NCT06419686
Study type Interventional
Source University Hospital, Gentofte, Copenhagen
Contact Julie V Warnøe, MD
Phone +4527282263
Email julie.vilhelmine.warnoee.nielsen@regionh.dk
Status Recruiting
Phase Phase 1
Start date January 1, 2024
Completion date July 2024